此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

全身磁共振成像和液体活检对癌症家族史患者早期癌症检测的分析

2026年11月2日 更新者:City of Hope Medical Center

用于早期癌症检测的全身 MRI 和液体活检

This study evaluates patient acceptability of whole body magnetic resonance imaging (WBM) and liquid biopsies (LB) in detecting early stage cancer in patients with a strong family history of cancer. Collecting family history and testing for genes passed on from parent to child (germline testing) can be used to predict the likelihood of a patient developing cancer. Currently, detection of early cancers focuses on screening specific organ systems such as breast and colon cancer. Magnetic resonance imaging (MRI) uses a large magnet and radio waves to look at organs and structures inside the body. Health care professionals use MRI scans to diagnose a variety of conditions, from torn ligaments to cancer. Liquid biopsy is test that analyzes blood samples to determine if cancer cells are present. This study may help researchers determine the feasibility of WBM and liquid biopsies to detect early stage cancer in patients that have a strong family history of cancer.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. To assess the acceptability of the approach of LB and WBM.

SECONDARY OBJECTIVES:

I. Determine the prevalence of WBM findings requiring additional imaging or invasive testing.

II. Determine the effect of germline testing, LB, and WBM on psychological distress and health-related quality of life (HR-QOL) at 6 months after testing compared with baseline.

EXPLORATORY OBJECTIVE:

I. Determine correlation between high-risk LB findings and cancer detected on WBM.

OUTLINE: This is an observational study.

Patients undergo WBM without contrast, blood sample collection for liquid biopsy, and complete surveys on study. Germline testing may also be performed on blood sample collected as standard of care or using the Precision Medicine protocol (Institutional Review Board [IRB] 96144).

研究类型

介入性

注册 (实际的)

100

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Duarte、California、美国、91010
        • City of Hope Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age >= 50 years, or age within 10 years of first degree relative with cancer at age of diagnosis (as long as age is >= 18)
  • Have a strong family history of cancer ( >= 2 first-degree relatives with cancer, one first and second degree relative with cancer in one lineage (side of family), or at least three first or second degree relatives with cancer in one lineage (side of the family). Non-melanoma skin cancer excluded from family history eligibility
  • Have a family history of early-onset cancer (age >40) in at least one first-degree relative
  • Willing to have 50 mL of blood (approximately 3.5 tablespoons) drawn (40 ml if germline testing already performed)
  • Able to undergo MRI (no implants, metal, or claustrophobia that would preclude MRI)
  • Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer
  • Positron emission tomography/computed tomography (PET/CT) or other whole body imaging modality (including combination of CT chest and abdomen) within 3 years
  • No signs/symptoms of possible cancer (e.g. hemoptysis, breast mass, blood per rectum, unexplained weight loss)
  • Willing to undergo standard of care genetic counseling and germline testing, or has already undergone genetic counseling and germline testing
  • Documented informed consent of the participant

Exclusion Criteria:

  • Unable to provide informed consent
  • Contraindications to MRI (implants, metal, or claustrophobia that would preclude MRI)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:放映
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Whole Body MRI and Liquid Biopsy

Patients undergo WBM without contrast and blood sample collection for liquid biopsy

Undergo blood sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集

Complete surveys

Undergo germline testing

其他名称:
  • 通过基因检测和咨询进行癌症风险评估

Undergo liquid biopsy testing

其他名称:
  • 血浆活检

Undergo whole body MRI without contrast

其他名称:
  • 无对比 WB-MRI
  • 无对比全身磁共振成像
  • 无对比的全身 MRI
  • 无造影剂的全身 MRI

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Acceptability of germline testing, liquid biopsy and whole body magnetic resonance imaging (WBM)
大体时间:Up to 6 months after WBM

Acceptability, as measured by the survey question "How satisfied are you with the research study overall?" and is defined as a score of 4 ("moderately acceptable) or 5 ("highly acceptable").

Up to 6 months after WBM

次要结果测量

结果测量
措施说明
大体时间
Prevalence of WBM findings requiring additional imaging or invasive testing
大体时间:Up to 6 months after WBM

Prevalence of WBM findings requiring additional imaging or invasive testing, described as a per participant percentage.

Up to 6 months after WBM
Psychological distress (Germline testing)A
大体时间:Up to 6 months after WBM

The effect of germline testing on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM
Psychological distress (Germline testing)B
大体时间:Up to 6 months after WBM

The effect of germline testing on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing.

Up to 6 months after WBM
Psychological distress (Liquid Biopsy)A
大体时间:Up to 6 months after WBM

The effect of LB on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM
Psychological distress (Liquid Biopsy)B
大体时间:Up to 6 months after WBM

The effect of LB on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing.

Up to 6 months after WBM
Psychological distress (WBM)A
大体时间:Up to 6 months after WBM

The effect of Whole Body MRI on Psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM
Psychological distress (WBM)B
大体时间:Up to 6 months after WBM

The effect of Whole Body MRI on Psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing.

Up to 6 months after WBM
Health Related Quality of Life (HRQOL/Germline)
大体时间:Up to 6 months after WBM

The effect of germline testing on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM
Health Related Quality of Life (HRQOL/LB)
大体时间:Up to 6 months after WBM

The effect of LB on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM
Health Related Quality of Life (HRQOL/WBM)
大体时间:Up to 6 months after WBM

The effect of WBM on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing.

Up to 6 months after WBM

其他结果措施

结果测量
措施说明
大体时间
Correlation between high-risk liquid biopsy findings and cancer detected on WBM
大体时间:Up to 6 months after WBM

Liquid biopsy (LB) test sensitivity and specificity calculated by comparing the LB results with the WBM results, with WBM results considered the gold standard. Confusion matrix statistics, such as positive predictive value, negative predictive value, and test accuracy examined. Results reported with their corresponding 95% confidence intervals.

Up to 6 months after WBM

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Dan Raz、City of Hope Medical Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年5月20日

初级完成 (估计的)

2027年9月20日

研究完成 (估计的)

2027年9月20日

研究注册日期

首次提交

2023年3月29日

首先提交符合 QC 标准的

2023年5月19日

首次发布 (实际的)

2023年5月22日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅